A Retrospective Analysis of the Impact of Adverse Event-Triggered Idelalisib Interruption and Dose Reduction on Clinical Outcomes in Patients with Relapsed/Refractory B-Cell Malignancies

Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia

(2019) Jeff P. Sharman et al.   JOURNAL OF CLINICAL ONCOLOGY

Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper

(2018) Antonio Cuneo et al.   HEMATOLOGICAL ONCOLOGY

Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial

(2017) Jeffrey A Jones et al.   Lancet Haematology

Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

(2016) M. Dreyling et al.   ANNALS OF ONCOLOGY

Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study

(2016) Gilles Salles et al.   HAEMATOLOGICA

Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study

(2016) Gilles Salles et al.   HAEMATOLOGICA

PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma

(2014) Ajay K. Gopal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia

(2014) Richard R. Furman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop

(2012) Roger G. Owen et al.   BRITISH JOURNAL OF HAEMATOLOGY

Novel Targeted Agents and the Need to Refine Clinical End Points in Chronic Lymphocytic Leukemia

(2012) Bruce D. Cheson et al.   JOURNAL OF CLINICAL ONCOLOGY

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

(2008) M. Hallek et al.   BLOOD